|
1
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases. Management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang N, Feng Y, Lau EP, et al: F-actin
reorganization and inactivation of rho signaling pathway involved
in the inhibitory effect of Coptidis Rhizoma on hepatoma
cell migration. Integr Cancer Ther. 9:354–364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kanai T, Hirohashi S, Upton MP, et al:
Pathology of small hepatocellular carcinoma. A proposal for a new
gross classification. Cancer. 60:810–819. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saftig P and Reiss K: The ‘A Disintegrin
And Metalloproteases’ ADAM10 and ADAM17: novel drug targets with
therapeutic potential? Eur J Cell Biol. 90:527–535. 2011.
|
|
6
|
Crawford HC, Dempsey PJ, Brown G, Adam L
and Moss ML: ADAM10 as a therapeutic target for cancer and
inflammation. Curr Pharm Des. 15:2288–2299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Postina R, Schroeder A, Dewachter I, et
al: A disintegrin-metalloproteinase prevents amyloid plaque
formation and hippocampal defects in an Alzheimer disease mouse
model. J Clin Invest. 113:1456–1464. 2004. View Article : Google Scholar
|
|
8
|
Naus S, Blanchet MR, Gossens K, Zaph C,
Bartsch JW, McNagny KM and Ziltener HJ: The
metalloprotease-disintegrin ADAM8 is essential for the development
of experimental asthma. Am J Respir Crit Care Med. 181:1318–1328.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murphy G: The ADAMs: signalling scissors
in the tumour microenvironment. Nat Rev Cancer. 8:929–941. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu X, Lu D, Scully M and Kakkar V: ADAM
proteins - therapeutic potential in cancer. Curr Cancer Drug
Targets. 8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Becherer JD and Blobel CP: Biochemical
properties and functions of membrane-anchored
metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol.
54:101–123. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang J, Bridges LC and White JM:
Selective modulation of integrin-mediated cell migration by
distinct ADAM family members. Mol Biol Cell. 16:4982–4991. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Doberstein K, Pfeilschifter J and Gutwein
P: The transcription factor PAX2 regulates ADAM10 expression in
renal cell carcinoma. Carcinogenesis. 32:1713–1723. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gaida MM, Haag N, Günther F, et al:
Expression of A disintegrin and metalloprotease 10 in pancreatic
carcinoma. Int J Mol Med. 26:281–288. 2010.PubMed/NCBI
|
|
15
|
Guo J, He L, Yuan P, et al: ADAM10
overexpression in human non-small cell lung cancer correlates with
cell migration and invasion through the activation of the Notch1
signaling pathway. Oncol Rep. 28:1709–1718. 2012.PubMed/NCBI
|
|
16
|
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and
Tao HQ: ADAM 10 is associated with gastric cancer progression and
prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW
and Liu TY: Increase of disintergin metalloprotease 10 (ADAM10)
expression in oral squamous cell carcinoma. Cancer Lett. 245:33–43.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee SB, Schramme A, Doberstein K, et al:
ADAM10 is upregulated in melanoma metastasis compared with primary
melanoma. J Invest Dermatol. 130:763–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Turner SL, Blair-Zajdel ME and Bunning RA:
ADAMs and ADAMTSs in cancer. Br J Biomed Sci. 66:117–128.
2009.PubMed/NCBI
|
|
20
|
Pawlik TM, Gleisner AL, Anders RA,
Assumpcao L, Maley W and Choti MA: Preoperative assessment of
hepatocellular carcinoma tumor grade using needle biopsy:
implications for transplant eligibility. Ann Surg. 245:435–442.
2007. View Article : Google Scholar
|
|
21
|
Okuda K, Ohtsuki T, Obata H, et al:
Natural history of hepatocellular carcinoma and prognosis in
relation to treatment. Study of 850 patients. Cancer. 56:918–928.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu Y, Chen W, Zhang Y, Hamburger AW, Pan H
and Zhang Z: Suppression of salivary adenoid cystic carcinoma
growth and metastasis by ErbB3 binding protein Ebp1 gene transfer.
Int J Cancer. 120:1909–1913. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu Q, Liu X, Chen W and Zhang Z:
Inhibiting adenoid cystic carcinoma cell growth and metastasis by
blocking the expression of ADAM 10 using RNA interference. J Transl
Med. 8:1362010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Llovet JM, Schwartz M and Mazzaferro V:
Resection and liver transplantation for hepatocellular carcinoma.
Semin Liver Dis. 25:181–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu W, Owusu L, Zang S, Zhang Y, Xin Y and
Yan C: GRP78 and GAL3, differentially regulated by lymph node
homogenates, as potential biomarkers for lymph node metastasis in
mouse hepatocellular carcinoma cells. Oncol Lett. 4:1374–1378.
2012.PubMed/NCBI
|
|
26
|
Gavert N, Conacci-Sorrell M, Gast D,
Schneider A, Altevogt P, Brabletz T and Ben-Ze’ev A: L1, a novel
target of β-catenin signaling, transforms cells and is expressed at
the invasive front of colon cancers. J Cell Biol. 168:633–642.
2005.
|
|
27
|
Arima T, Enokida H, Kubo H, et al: Nuclear
translocation of ADAM-10 contributes to the pathogenesis and
progression of human prostate cancer. Cancer Sci. 98:1720–1726.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jorissen E, Prox J, Bernreuther C, et al:
The disintegrin/metalloproteinase ADAM10 is essential for the
establishment of the brain cortex. J Neurosci. 30:4833–4844. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jacobsen KT, Adlerz L, Multhaup G and
Iverfeldt K: Insulin-like growth factor-1 (IGF-1)-induced
processing of amyloid-β precursor protein (APP) and APP-like
protein 2 is mediated by different metalloproteinases. J Biol Chem.
285:10223–10231. 2010.
|
|
30
|
Venkataramani V, Rossner C, Iffland L, et
al: Histone deacetylase inhibitor valproic acid inhibits cancer
cell proliferation via down-regulation of the alzheimer amyloid
precursor protein. J Biol Chem. 285:10678–10689. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fan X, Liu Y, Jiang J, et al: miR-20a
promotes proliferation and invasion by targeting APP in human
ovarian cancer cells. Acta Biochim Biophys Sin. 42:318–324. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan Y, Han C, Wang C, et al: ADAM10
promotes pituitary adenoma cell migration by regulating cleavage of
CD44 and L1. J Mol Endocrinol. 49:21–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Anderegg U, Eichenberg T, Parthaune T, et
al: ADAM10 is the constitutive functional sheddase of CD44 in human
melanoma cells. J Invest Dermatol. 129:1471–1482. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
DeCicco-Skinner KL, Nolan SJ, Deshpande
MM, Trovato EL, Dempsey TA and Wiest JS: Altered prostanoid
signaling contributes to increased skin tumorigenesis in Tpl2
knockout mice. PLoS One. 8:e562122013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Massi D, Tarantini F, Franchi A, et al:
Evidence for differential expression of Notch receptors and their
ligands in melanocytic nevi and cutaneous malignant melanoma. Mod
Pathol. 19:246–254. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gutwein P, Oleszewski M, Mechtersheimer S,
Agmon-Levin N, Krauss K and Altevogt P: Role of Src kinases in the
ADAM-mediated release of L1 adhesion molecule from human tumor
cells. J Biol Chem. 275:15490–15497. 2000. View Article : Google Scholar : PubMed/NCBI
|
